Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003238 | 1.00 | L3MBTL1 (0.49) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL8599619 | 1.00 | L3MBTL1 (0.49) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL13003240 | 0.92 | L3MBTL1 (0.49) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL13003236 | 0.92 | L3MBTL1 (0.49) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL13003235 | 0.92 | L3MBTL1 (0.49) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL13060336 | 0.84 | CYP4F2 (0.44) | L3MBTL1NPSR1TSHRALDH1A1MAPK1 | |
| SCHEMBL14095930 | 0.84 | CYP4F2 (0.44) | L3MBTL1NPSR1TSHRALDH1A1MAPK1 | |
| SCHEMBL8617200 | 0.79 | ALDH1A1 (0.48) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL16254640 | 0.78 | L3MBTL1 (0.39) | L3MBTL1NPSR1TSHRALDH1A1TDP1 | |
| SCHEMBL14096224 | 0.78 | ALDH1A1 (0.42) | L3MBTL1NPSR1TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748125-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748125-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-7851220-B2 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | INTREXON CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-09-04 | — | — | US | disclosed |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-08-14 | — | — | US | disclosed |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | HORMANN ROBERT E | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | L3MBTL1 572/4885NPSR1 1056/4885TSHR 224/4885 |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | L3MBTL1 572/4885NPSR1 1056/4885TSHR 224/4885 |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | NR5A1, NR0B2, NR0B1 | L3MBTL1 764/4885NPSR1 454/4885TSHR 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.